Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - raxone
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp9a5ac6d518a24ab2e0257a8b57ce793b
identifier: http://ema.europa.eu/identifier
/EU/1/15/1020/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Raxone 150 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-9a5ac6d518a24ab2e0257a8b57ce793b
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/15/1020/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - raxone
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Raxone contains a substance called idebenone.
Idebenone is used to treat vision impairment in adults and adolescents with an eye disease called Leber s Hereditary Optic Neuropathy (LHON).
Treatment with Raxone can restore the ability of cells to produce energy and so allow inactive eye cells to work again. This can lead to some improvement in lost eyesight.
Do not take Raxone
Warnings and precautions
Talk to your doctor or pharmacist before taking Raxone if:
Change in urine colour
Raxone may make your urine become reddish brown. This change in colour is harmless it does not mean your treatment needs to change. However, the change in colour could mean that you have problems with your kidneys or bladder.
Tests Your doctor will check your eye-sight before you start taking this medicine and then at regular visits while you are taking it.
Children and adolescents This medicine should not be used in children This is because it is not known if Raxone is safe or works in patients under 12 years of age.
Other medicines and Raxone Some medicines may interact with Raxone. Tell your doctor if you are taking, have recently taken or might take any other medicines, especially any of the following:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines Raxone is not expected to affect your ability to drive or use machines.
Raxone contains lactose and sunset yellow (E110)
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
How much to take The recommended dose is 2 tablets three times a day - this is a total of 6 tablets per day.
Taking this medicine
If you take more Raxone than you should If you take more Raxone than you should, talk to your doctor straight away.
If you forget to take Raxone If you forget a dose, skip the missed dose. Take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.
If you stop taking Raxone Talk to your doctor before you stop taking this medicine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effect may happen with this medicine:
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Unknown frequency (frequency cannot be estimated from the available data):
Reporting of side effects
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system in Appendix V. By reporting side effecs you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the bottle after EXP . The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Raxone contains
What Raxone looks like and contents of the pack
Marketing Authorisation Holder Chiesi Farmaceutici S.p.A. Via Palermo 26/A 43122 Parma Italy
Manufacturer Santhera Pharmaceuticals (Deutschland) GmbH Marie-Curie Strasse 8 79539 L rrach Germany Tel: +49 (0) 7621 1690 Email: office@santhera.com
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Chiesi sa/nv
T l/Tel: + 32 (0)2 788 42 Lietuva Chiesi Pharmaceuticals GmbH
Tel: + 43 1 4073
Chiesi Bulgaria EOOD
Te .: + 359 29201Luxembourg/Luxemburg Chiesi sa/nv
T l/Tel: + 32 (0)2 788 42 esk republika Chiesi CZ s.r.o.
Tel: + 420 261221Magyarorsz g Chiesi Hungary Kft.
Tel.: + 36-1-429 1Danmark Chiesi Pharma AB
Tlf: + 46 8 753 35 Malta Chiesi Farmaceutici S.p.A.
Tel: + 39 0521 2Deutschland Chiesi GmbH
Tel: + 49 40 89724-0
Nederland Chiesi Pharmaceuticals B.V.
Tel: + 31 88 501 64 Eesti Chiesi Pharmaceuticals GmbH
Tel: + 43 1 4073Norge Chiesi Pharma AB
Tlf: + 46 8 753 35
Chiesi Hellas AEBE
: + 30 210 6179 sterreich Chiesi Pharmaceuticals GmbH
Tel: + 43 1 4073Espa a Chiesi Espa a, S.A.U.
Tel: + 34 93 494 8Polska Chiesi Poland Sp. z.o.o.
Tel.: + 48 22 620 1France Chiesi S.A.S.
T l: + 33 1 47688Portugal Chiesi Farmaceutici S.p.A.
Tel: + 39 0521 2Hrvatska Chiesi Pharmaceuticals GmbH
Tel: + 43 1 4073Rom nia Chiesi Romania S.R.L.
Tel: + 40 212023Ireland Chiesi Farmaceutici S.p.A.
Tel: + 39 0521 2Slovenija CHIESI SLOVENIJA d.o.o.
Tel: + 386-1-43 00 sland Chiesi Pharma AB
S mi: +46 8 753 35 Slovensk republika Chiesi Slovakia s.r.o.
Tel: + 421 259300Italia Chiesi Italia S.p.A.
Tel: + 39 0521 2Suomi/Finland Chiesi Pharma AB
Puh/Tel: +46 8 753 35
Chiesi Farmaceutici S.p.A.
: + 39 0521 2Sverige Chiesi Pharma AB
Tel: +46 8 753 35 Latvija Chiesi Pharmaceuticals GmbH
Tel: + 43 1 4073United Kingdom (Northern Ireland)
Chiesi Farmaceutici S.p.A.
Tel: + 39 0521 2This leaflet was last revised in
This medicinal product has been authorised under exceptional circumstances .
This means that due to the rarity of the disease it has not been possible to obtain complete information on this medicinal product. The European Medicines Agency will review any new information which may become available every year and this leaflet will be updated as necessary.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-9a5ac6d518a24ab2e0257a8b57ce793b
Resource Composition:
Generated Narrative: Composition composition-en-9a5ac6d518a24ab2e0257a8b57ce793b
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1020/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - raxone
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp9a5ac6d518a24ab2e0257a8b57ce793b
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp9a5ac6d518a24ab2e0257a8b57ce793b
identifier:
http://ema.europa.eu/identifier
/EU/1/15/1020/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Raxone 150 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en